Modulating the Internalization of Bacille Calmette-Guerin by Cathelicidin in Bladder Cancer Cells

被引:11
作者
Choi, Se Young
Kim, Soon-Ja
Chi, Byung Hoon
Kwon, Jong Kyou
Chang, In Ho
机构
[1] Chung Ang Univ Hosp, Dept Urol, Coll Med, Seoul 156755, South Korea
[2] Chung Ang Univ, Grad Sch, Biomed Sci, Dept Med, Seoul 156756, South Korea
基金
新加坡国家研究基金会;
关键词
ANTIMICROBIAL PEPTIDES; EPITHELIAL-CELLS; URINARY-TRACT; INFECTION; LL-37; BCG;
D O I
10.1016/j.urology.2014.12.028
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To confirm the role of cathelicidin (LL-37) in the internalization of bacille Calmette-Guerin (BCG) into bladder cancer cells. METHODS Enzyme-linked immunosorbent assay and reverse transcription polymerase chain reaction analysis evaluated the changes in protein and messenger ribonucleic acid (RNA) expression with BCG incubation after LL-37 pretreatment in 5637 and T24 human bladder cancer cells. The internalization rate was evaluated by a double immunofluorescence assay, and confocal microscopy confirmed the function of LL-37 in BCG internalization. We also investigated the difference in internalization rates and cell viability between LL-37, anti-LL-37 antibody, and LL-37 plus anti-LL-37 antibody. RESULTS The levels of LL-37 increased after BCG exposure in bladder cancer cells in dose-and time-dependent manners. Increasing LL-37 levels using recombinant LL-37 protein further dose dependently decreased BCG internalization in both cell lines. The internalization rates of BCG after LL-37 instillation were lower compared with the controls, and the internalization rate of BCG after anti-LL-37 antibody instillation was significantly higher compared with the controls in both cell lines (P <.05). Viability of LL-37 plus BCG group was higher compared with the BCG-alone group. The anti-LL-37 antibody plus BCG group had decreased cell viability compared with the BCG-alone group in both cell lines. CONCLUSION Bladder cancer cells produce cathelicidin when infected with BCG and upregulate cathelicidin to defend against BCG by inhibiting its internalization. Blocking the action of cathelicidin may increase the internalization and effectiveness of BCG in reducing bladder cancer cell proliferation. (C) 2015 Elsevier Inc.
引用
收藏
页码:964.e7 / 964.e12
页数:6
相关论文
共 14 条
[1]   INTERNALIZATION OF BACILLE CALMETTE-GUERIN BY BLADDER-TUMOR CELLS [J].
BECICH, MJ ;
CARROLL, S ;
RATLIFF, TL .
JOURNAL OF UROLOGY, 1991, 145 (06) :1316-1324
[2]   Cathelicidin LL-37: A Multitask Antimicrobial Peptide [J].
Bucki, Robert ;
Leszczynska, Katarzyna ;
Namiot, Andrzej ;
Sokolowski, Wojciech .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2010, 58 (01) :15-25
[3]   The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection [J].
Chromek, Milan ;
Slamova, Zuzana ;
Bergman, Peter ;
Kovacs, Laszlo ;
Podracka, L'udmila ;
Ehren, Ingrid ;
Hokfelt, Tomas ;
Gudmundsson, Gudmundur H. ;
Gallo, Richard L. ;
Agerberth, Birgitta ;
Brauner, Annelie .
NATURE MEDICINE, 2006, 12 (06) :636-641
[4]   Human antimicrobial peptides LL-37 and human β-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus [J].
Crack, L. R. ;
Jones, L. ;
Malavige, G. N. ;
Patel, V. ;
Ogg, G. S. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2012, 37 (05) :534-543
[5]  
deBoer EC, 1996, CYTOMETRY, V25, P381, DOI 10.1002/(SICI)1097-0320(19961201)25:4<381::AID-CYTO10>3.3.CO
[6]  
2-M
[7]   The fate of bacillus Calmette-Guerin after intravesical instillation [J].
Durek, C ;
Richter, E ;
Basteck, A ;
Rüsch-Gerdes, S ;
Gerdes, J ;
Jocham, D ;
Böhle, A .
JOURNAL OF UROLOGY, 2001, 165 (05) :1765-1768
[8]   Human β-defensin 2 may inhibit internalisation of bacillus Calmette-Guerin (BCG) in bladder cancer cells [J].
Kim, Jung Hoon ;
Kim, Soon-Ja ;
Lee, Kyung Mee ;
Chang, In Ho .
BJU INTERNATIONAL, 2013, 112 (06) :781-790
[9]   Expression and secretion of cathelicidin LL-37 in human epithelial cells after infection by Mycobacterium bovis bacillus Calmette-Guerin [J].
Mendez-Samperio, Patricia ;
Miranda, Elena ;
Trejo, Artemisa .
CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (09) :1450-1455
[10]  
RATLIFF TL, 1987, CANCER RES, V47, P1762